Loading...
 

Volume 33, Issue 2, June 2022



Sign in to download the Issue in PDF format.

Mediterr J Rheumatol 2022;33(2):173-5
Hyperinflammation due to COVID-19 and the Targeted Use of Interleukin-1 Inhibitors
Authors Information

1Departments of Rheumatology and Research and Development, Dudley Group NHS Foundation Trust (Teaching Trust of the University of Birmingham, UK), Russells Hall Hospital, Dudley, West Midlands, United Kingdom

2Centre for Epidemiology versus Arthritis, University of Manchester, Manchester, United Kingdom

AY Gasparyan, GD Kitas

Abstract

This paper has no abstract.

Cite this article as: Gasparyan AY, Kitas GD. Hyperinflammation due to COVID-19 and the Targeted Use of Interleukin-1 Inhibitors. Mediterr J Rheumatol 2022;33(2):173-5

Article Submitted: 15 Jun 2022; Article Accepted: 16 Jun 2022; Available Online: 30 Jun 2022

https://doi.org/10.31138/mjr.33.2.173

This work is licensed under a Creative Commons Attribution 4.0 International License.

©Gasparyan AY, Kitas GD.